KPTIKaryopharm Therapeutics Inc.vs its industry peers
A metric-by-metric comparison of Karyopharm Therapeutics Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KPTI본 종목 | $39M#4 | — | — | 0.3x#1 | 0.6%#3 | -156.5%#5 | -62.1%#2 | — | — | — | -72.2%#7 | — |
| ANVS | $49M#1 | — | — | — | — | -17.3%#3 | — | — | — | — | -50.4%#3 | — |
| SCYX | $41M#2 | 14.8x#1 | 0.6x#3 | 2.0x#5 | 449.9%#1 | 59.6%#1 | -78.0%#3 | -12.9%#1 | — | 7#1 | -52.1%#4 | — |
| CELU | $39M#3 | — | — | 1.5x#4 | -51.0%#5 | -58.4%#4 | -230.9%#4 | — | -398.1%#2 | — | -38.8%#2 | — |
| FLNA | $34M#5 | — | 0.5x#1 | 0.8x#3 | 277.6%#2 | -273.7%#6 | -232.0%#5 | -133.5%#4 | — | — | -66.4%#6 | — |
| RMTI | $32M#6 | 267.0x#2 | 0.9x#4 | 0.5x#2 | -31.8%#4 | -1007.1%#7 | -6.8%#1 | -15.1%#2 | -14.0%#1 | 4#2 | -52.3%#5 | — |
| BRNS | $31M#7 | — | 0.5x#2 | — | -100.0%#6 | -8.8%#2 | — | -116.4%#3 | — | — | -37.0%#1 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice